Angiogenesis-related agents in esophageal cancer

Bibliography

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-36
   PubMed Web of Science ®Google Scholar
• Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62(2):118-28
   PubMed Web of Science ®Google Scholar
• Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 Suppl 15):2-8
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92(3):549-55
   PubMed Web of Science ®Google Scholar
• Engel LS, Chow WH, Vaughan TL, Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95(18):1404-13
   PubMed Web of Science ®Google Scholar
• Pandeya N, Williams G, Green AC, Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009;136(4):1215-24; e1211-2
   PubMed Web of Science ®Google Scholar
• Edelstein ZR, Farrow DC, Bronner MP, Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133(2):403-11
   PubMed Web of Science ®Google Scholar
• Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143(3):199-211
   PubMed Web of Science ®Google Scholar
• Gammon MD, Schoenberg JB, Ahsan H, Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89(17):1277-84
   PubMed Web of Science ®Google Scholar
• Zhai R, Chen F, Liu G, Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010;28(14):2445-51
   PubMed Web of Science ®Google Scholar
• Lanuti M, Liu G, Goodwin JM, A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14(10):3216-22
   PubMed Web of Science ®Google Scholar
• Pottern LM, Morris LE, Blot WJ, Esophageal cancer among black men in Washington, D.C. I. Alcohol, tobacco, and other risk factors. J Natl Cancer Inst 1981;67(4):777-83
   PubMed Web of Science ®Google Scholar
• Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100(16):1184-7
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349(23):2241-52
   PubMed Web of Science ®Google Scholar
• Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol 2004;31(4):476-86
   PubMed Web of Science ®Google Scholar
• Miller CT, Moy JR, Lin L, Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 2003;9(13):4819-25
   PubMed Web of Science ®Google Scholar
• Suo Z, Su W, Holm R, Nesland JM. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anticancer Res 1995;15(6B):2797-8
   PubMed Web of Science ®Google Scholar
• Maley CC, Rustgi AK. Barrett's esophagus and its progression to adenocarcinoma. J Natl Compr Canc Netw 2006;4(4):367-74
   PubMedGoogle Scholar
• Ando N, Ozawa S, Kitagawa Y, Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232(2):225-32
   PubMed Web of Science ®Google Scholar
• Hulscher JB, van Sandick JW, de Boer AG, Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347(21):1662-9
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339(27):1979-84
   PubMed Web of Science ®Google Scholar
• Bosset JF, Gignoux M, Triboulet JP, Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337(3):161-7
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz MK, Stuschke M, Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27(6):851-6
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72(1):37-41
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24(18):2903-9
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, cunningham D, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20(8):1996-2004
   PubMed Web of Science ®Google Scholar
• Webb A, Cunningham D, Scarffe JH, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15(1):261-7
   PubMed Web of Science ®Google Scholar
• Ilson DH. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J Clin Oncol 2002;20(8):1962-4
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358(1):36-46
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24(31):4991-7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;362(9):858-9
   Web of Science ®Google Scholar
• Enzinger PC, Burtness B, Hollis D, CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. In ASCO; 2010
   Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8(8):579-91
   PubMed Web of Science ®Google Scholar
• Dallas NA, Fan F, Gray MJ, Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007;26(3-4):433-41
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103
   PubMed Web of Science ®Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD, VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101(12):4878-86
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O′Connell MJ, Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29(1):11-16
   PubMed Web of Science ®Google Scholar
• De Gramont A, Van cutsem E, Tabernero J, AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. In Gastrointestinal Cancers Symposium; 2011
   Google Scholar
• Kitadai Y, Haruma K, Tokutomi T, Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4(9):2195-200
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Peters JH, Kuramochi H, Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg 2006;141(5):476-81; discussion 481-2
   PubMed Web of Science ®Google Scholar
• Inoue K, Ozeki Y, Suganuma T, Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79(2):206-13
   PubMed Web of Science ®Google Scholar
• Oshima Y, Yajima S, Yamazaki K, Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg 2010;16(6):389-93
   PubMed Web of Science ®Google Scholar
• Barclay C, Li AW, Geldenhuys L, Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene. Clin Cancer Res 2005;11(21):7683-91
   PubMed Web of Science ®Google Scholar
• Kozlowski M, Kowalczuk O, Milewski R, Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg 2010;38(3):260-7
   PubMed Web of Science ®Google Scholar
• Lurje G, Leers JM, Pohl A, Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010;251(5):857-64
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7(4):335-45
   PubMedGoogle Scholar
• Brufsky AM, Hurvitz S, Perez E, RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29(32):4286-93
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28(13):2137-43
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van cutsem E, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968-76
   PubMed Web of Science ®Google Scholar
• Husain H, Lurje G, Yang D, Ethnicity is associated with recurrence in patients with resected gastric cancer. In ASCO; 2008
   Google Scholar
• Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010;6(7):1085-94
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelsen MD, Rosenberg J, Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368(9544):1329-38
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501-13
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kang YK, Kang WK, Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 29(6):1449-58
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Sommers SR, Fisher WB, Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. In ASCO; 2011
   Google Scholar
• Carlomagno F, Anaganti S, Guida T, BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98(5):326-34
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O′Dwyer PJ, Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18):2947-51
   PubMed Web of Science ®Google Scholar
• Ilson D, Janjigian Y, Shah MA, Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: response observed in adenocarcinoma. In Gastrointestinal Cancers Symposium; 2011
   Google Scholar
• Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9(2):263-71
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth J, Krssak M, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68(12):4774-82
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15(3):232-9
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8(4):210-21
   PubMed Web of Science ®Google Scholar
• Saigusa S, Tanaka K, Toiyama Y, Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol 2011;23(5):323-32
   Web of Science ®Google Scholar
• Kojima M, Ishii G, Atsumi N, Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99(8):1578-83
   PubMed Web of Science ®Google Scholar
• Miles D, Harbeck N, Escudier B, Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2010;29(1):83-8
   PubMed Web of Science ®Google Scholar
• Horsley L, Marti K, Jayson GC. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 2012;8(3):283-93
   PubMed Web of Science ®Google Scholar
• Jubb AM, Hurwitz HI, Bai W, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24(2):217-27
   PubMed Web of Science ®Google Scholar
• Holden SN, Ryan E, Kearns A, Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC). In ASCO; 2005
   Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Shah MA, Ramanathan RK, Ilson TH, Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24(33):5201-6
   PubMed Web of Science ®Google Scholar
• El-Rifai W, Frierson HF, Jr., Moskaluk CA, Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121(3):592-8
   PubMed Web of Science ®Google Scholar
• Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359(9319):1727-33
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27(30):5062-7
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29(13):1715-21
   PubMed Web of Science ®Google Scholar
• Schuhmacher C, Gretschel S, Lordick F, Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28(35):5210-18
   PubMed Web of Science ®Google Scholar
• Gaast AV, van Hagen P, Hulshof M, Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. In ASCO; 2010
   Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086-92
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666-73
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26(9):1435-42
   PubMed Web of Science ®Google Scholar
• Jatoi A, Murphy BR, Foster NR, Medical Research Council Oesophageal Cancer Working Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006;17(1):29-34
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C, Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19(8):1450-7
   PubMed Web of Science ®Google Scholar
• Shah MA, Jhawer M, Ilson DH, Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29(7):868-74
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Ryan DP, Regan EM, Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. In ASCO Annual Metting; 2008
   Google Scholar
• El-Rayes BF, Zalupski M, Bekai-Saab T, A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 21(10):1999-2004
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Fidias P, Meyerhardt K. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. In ASCO; 2006
   Google Scholar
• Hanrahan EO, Linn HY, Kim ES, Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28(2):193-201
   PubMed Web of Science ®Google Scholar
• Kopetz S, Hoff PM, Morris JS, Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28(3):453-9
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8
   PubMed Web of Science ®Google Scholar
• Ronzoni M, Manzoni M, Mariucci S, Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010;21(12):2382-9
   PubMed Web of Science ®Google Scholar